Mergers & Acquisitions ·
PTC Therapeutics entered into an asset purchase agreement to acquire Sangamo Therapeutics' assets related to ST-920, a…
PTCTPtc Therapeutics, Inc.
PTC Therapeutics entered into an asset purchase agreement to acquire Sangamo Therapeutics' assets related to ST-920, a one-time AAV gene therapy candidate for Fabry disease. The transaction involves an upfront payment of $111 million and up to $100 million in contingent milestone payments: $80 million upon FDA accelerated approval and $20 million upon full approval of the biologics license application based on STAAR study data. PTC was selected as the winning bidder in Sangamo's Chapter 11 bankruptcy auction. Closing is subject to Bankruptcy Court approval, with a hearing scheduled for September 10, 2026, and must occur by October 15, 2026. This company operates in the biotechnology industry, developing therapies for rare genetic diseases.